Last reviewed · How we verify
Risedronate Sodium 150 MG
At a glance
| Generic name | Risedronate Sodium 150 MG |
|---|---|
| Also known as | Code A |
| Sponsor | Wake Forest University Health Sciences |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery (PHASE3)
- Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT (PHASE2)
- Weight Loss With Risedronate for Bone Health (PHASE4)
- Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy (PHASE3)
- Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women (PHASE2)
- A Study of Monthly Risedronate for Osteoporosis (PHASE3)
- Bone Microarchitecture in Osteopenic Postmenopausal Women (PHASE4)
- Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Risedronate Sodium 150 MG CI brief — competitive landscape report
- Risedronate Sodium 150 MG updates RSS · CI watch RSS
- Wake Forest University Health Sciences portfolio CI